Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Fusion Pharma Canada

Fusion Pharmaceuticals is a clinical stage company committed to developing next generation precision radiopharmaceuticals for the diagnosis and treatment of human cancers with unmet medical needs.  The Company’s lead product, FPX-01, combines an alpha radionuclide with the precise targeting of an antibody to cause selective cytotoxicity of tumor cells.  FPX-01 will be entering Phase 2 clinical development in H2, 2015.

Website:
www.fusionpharma.com
Year Founded
2014
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
The FPX-01 program represents a true theranostic approach. By leveraging its expertise in radiochemistry and biology, and utilizing different isotopes, Fusion has produced variants of FPX-01 that act as either diagnostic or therapeutic agents. For human proof-of-concept, Fusion initiated a Phase I imaging trial in Canada. Using Iodine-124 as a probe, this trial was designed to confirm that FPX-01 binds and internalizes to solid tumors expressing the receptor target as determined through PET/CT imaging. Initial results from this trial demonstrate that FPX-01 can identify metastatic lesions not previously identified through other imaging techniques. These data corroborate previous preclinical in vivo data which indicated that the radioactivity-associated with FPX-01 accumulated within tumours over several days. Following the completion of the Phase 1 imaging trial and additional preclinical studies planned for H1 2015, Fusion will file an IND in H2 2015 that will be designed to achieve breakthrough status in NSCLC. For therapy, FPX-01 will be radiolabeled with an alpha-emitting isotope. Preclinical xenograph studies, using only a single administration of isotope demonstrated tumor regression, with minimal toxicity at any dose level. It is expected that the IND-opening trial will be a Phase I/II therapeutic study in approximately 100 patients with non-small cell lung cancer (NSCLC), addressing a major unmet medical need.
Alliance & Collaborations
Ontario Institute for Cancer Research
Supporting Metrics or Evidence
Clinical and pre-clinical data.
Current Financing Needs
Series A $15M
Current Timeline
H2 2015: Phase 2 IND
Current Investors
Centre for Probe Development and Commercialization
IP Status
The FPX-01 antibody is protected worldwide via multiple granted patents. Additional combinations of delivery vehicles, conjugation/chelation technologies and radioisotope variation are routinely considered and evaluated for their proprietary nature and if appropriate, patent applications are filed. Regulatory exclusivity will extend FPX-01 protection in the US market.
Management Team Highlights
Frank Gleeson, CEO. Founding CEO of Fusion Pharma, DVLR Therapeutics, Verio Therapeutics (sold to Fate Therapeutics in 2010) and former Partner with MDS Capital Corp. Mr. Gleeson has raised over $200M in syndicated financings.
Michael Cross

Genrich

Genrich is a Multi-Family office founded and based in Long Beach California with additional offices in New York Toronto and London. The firm is looking to make equity and venture debt investments into companies in the life science space ranging from $2-$2 million over the lifetime of the investment often set up in tranches. Ideal candidates will be located 2 hours driving distance from one of the firm?s offices Boston and Chicago will also be considered. The firm is actively seeking new investment opportunities.
Website:
www.genrichinc.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
John Nelson
Managing Director 

Golden Seeds

Golden Seeds is an investment group that was founded in 25 and is headquartered in New York with other offices in Boston Silicon Valley and Texas. The group currently invests out of the Golden Seeds angel network and the Golden Seeds venture funds. The group has managed 3 venture funds that are Golden Seeds Fund LP Golden Seeds Fund 2 LP and Innovate New York LP Fund. The Golden Seeds angel network has 32 members of which 1 are life science investors. Golden Seeds invests in companies with a female founder or CEO or with women in other C-level positions or with at least 1% of equity owned by women. Golden Seeds prefers to invest in companies with a valuation under $5 million, the group?s first-round equity investments generally range from $ .25 million to $2 million. The group invests in companies based across the US and Canada.
Website:
www.gmail.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Bill Whitaker
Managing Director Co-Chair Life Science Section 

Green Park & Golf Ventures

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Website:
www.gpgventures.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Clay Heighten
Founding Partner 
JR Garcia
Principal 
Carl Soderstrom
Founding Partner 

H.I.G. BioVentures

H.I.G. BioVentures is the life science investment affiliate of H.I.G. Capital and has offices across the USA. H.I.G. BioVentures has assets under management of $4m and is investing from its second fund which closed at $268m in 212. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $2m over the life of an investment. While most of H.I.G. BioVentures? portfolio companies are US-based the firm will consider opportunities worldwide.
Website:
www.higbio.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Enoch Kariuki
Vice President 

Hercules Technology Growth Capital Inc.

Hercules Technology Growth Capital is a Private Equity company founded in 23 Headquartered in Palo Alto California with additional offices in Boston Boulder New York and McLean. The firm manages an evergreen structure and primarily provides high-growth companies in the life science space with senior secured debt financing. The firm can allocate up to $5 million per investment. The firm is very flexible with deal structures that can be customized to help companies reach their key milestones. The firm primarily invests in companies headquartered in the US but has the ability to invest overseas as well.
Website:
www.htgc.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Janice Borque
Managing Director Life Sciences 

Horizon Technology Finance United States

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

Website:
www.horizontechfinance.com
Year Founded
2003
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jerry Michaud

Hub Angels Investment Group

Hub Angels Investment Group is an angel group that was founded in 2 and is based in Cambridge Massachusetts. The firm manages a fund structure and recently closed its 4th fund making the total AUM of the group around $4 million. The firm makes investments ranging from $25 to $5 in equity for companies that are at least 12 months old. The firm makes investments ranging from four to eight years and prefers to invest in companies whose valuation does not exceed $1 million. Hub angels plans on making approximately 3 allocations over the next 6-9 months with stated interest in diagnostics and medical device companies.
Website:
www.gmail.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Randy Barko
Member 

Iliad Ventures

Iliad Ventures is a private investment firm funded entirely by its partners that is based in New York City. The firm is looking to make equity investment into early and mid-stage life science companies ranging from $5 to 2 million initially. The firm looks to get involved in Seed and Series A Rounds. The firm could make as many as 6 investments over the next 12 months and looks to invest in companies located throughout the United States Europe and Israel.
Website:
www.iliad-ventures.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Steve Tsetsekos
General Partner 

Immunova LLC United States

Immunova is a startup with  an IP portfolio licensed from Yale and the Johns Hopkins Universities.

Immunova's technology platform has a unique capability to deliver one or more drugs to the tumor/disease microenvironment. The drugs can be proteins, small molecules or nucleic acids. The delivery platfrom has demonstatable advantages over other delivery systems. The technology has applications in oncology and inflammation.

The company's lead asset is positioned in oncology. IMM-01, consists of two drugs that (a) undermine the tumor micorenvironment and (b) increase anti-tumor cell mediated immunity. This asset is capable of curing mice of metastatic disease. Further, it significantly enhances the activites of immune checkpoint inhibitors. It is non toxic.

The company is seeking investment and R&D partners. Immunova has defined the path to a Phase I/IIa multidose trial which could initiate within 15 months of funding. Immunova is also seeking partners who wish to validate this platform in oncology and inflammation.

Website:
www.immunova.net
Year Founded
2011
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
Immunova’s platform enables effective drug combination therapy. Chemically diverse drugs such as biologics and small molecules can be formulated and encapsulated in a liposome and thereby delivered systemically to a target cell or environment where each encapsulated API can be released independently in a controlled or tuneable manner using our proprietary technology. Importantly, this approach also potentiates existing or novel therapies often increasing their therapeutic index. LipoGel-TR is a hybrid platform of liposomes and PLGA nanoparticle delivery systems designed to possess the positive features of each platform while minimizing the negative aspects. Many of the building blocks required to make a LipoGel can be bought preassembled and GMP from third party providers thus shortening development timelines. We have demonstrated the superiority of LipoGels in numerous in vitro assays (drug loading and release and potency) and animal models of disease (efficacy and survival). Using our technology we have demonstrated that we can (a) direct one or more drugs to the TME, (b) increase drug synergies, efficacy and potency of chemo and immunotherapies, (c) decrease drug toxicity, (d) increase immune cell activity and (e) generate new intellectual property.
Alliance & Collaborations
The company is actively seeking partners in oncology and inflammation.
Supporting Metrics or Evidence
The technology has been published in high profile journals and the founder actively collaborates with numerous scientists at leading institutions. The Company’s initial focus is cancer immunotherapy: delivery of molecules that modulate immunity, positively and negatively, in order to undermine the tumor microenvironment and allow the immune system to keep pace with tumor evolution and thus be primed to eradicate disease. Our lead asset, IMM01: • Is targeted to and accumulates in tumors; • Encapsulated APIs are slowly released over 7 days and this can be further modulated; • Dramatically increases potency and efficacy: in a murine model of metastatic disease, IV delivery of IMM-01 results in 85% survival of IMM-01-treated mice at day 60 whereas all untreated mice, as well as mice treated with the drugs in solution, have died by day 30; • Increases immune infiltrate within the tumor which correlates with good patient outcomes • Significantly increases the potency of anti-PD1 and anti-CTLA4 mAb therapy in a mouse model of metastatic disease supporting published MoA studies • Is not toxic; there are no signs of renal, hepatic, bronchial, RBC or leukocyte toxicity when IMM-01 is administered to mice at high doses.
Current Financing Needs
Immunova is seeking $8-10M to fund operations for three years and including a phase I/IIa clinical trial
Current Timeline
Pending financing, IMM-01 is ca 15 months from a Phase I/IIa clinical trial
Current Investors
Angel-backed to date
IP Status
The company has licensed 4 granted and 3 pending patents
Recent Milestones
Q3 2014 • Demonstration of synergy with checkpoint inhibitors • New patent filed • Patent granted • Academic founder noted as a bioentrepreneur to watch by Nature Biotechnology Q4 2014 • First phase technology transfer to CMO • Identified lead clinical trial site and PI • Determined drug needs for clinical trial • Regulator engaged for ‘preIND meeting’
Management Team Highlights
The Company has recruited an impressive team that has an established and successful record of building companies. The management, advisors and scientific founders have an established network of both pharmaceutical and medical contacts and extensive experience running biotechnology firms and executing clinical trials. For reference, the following biotech startups founded/managed/invested in by Immunova Management or Advisors, were acquired prior to FDA approval: • Neurovir Therapeutics, Inc. – Acquired by MediGene AG for $42M • Nurel Therapeutics – acquired by DyaMid AB (undisclosed) • Proximagen plc. – Acquired by Upsher Smith for $550M • PharmaGenics Inc. – acquired by Genzyme for $28M • Prostagen– acquired by Cytogen (undisclosed)
Brian Horsburgh